Figure 4.
The relevance of NOTCH2-Va expression to the clinical outcome of patients with AML. The relevance of NOTCH2-Va expression to clinical outcome was estimated in the subgroup of patients within each cytogenetic risk group. As A demonstrates, a patient group expressing higher than median levels of NOTCH2-Va has a similar prognosis as the adverse risk group of patients. B shows the overall survival of AML patients with an intermediate risk cytogenetic profile. When dividing patients into 4 categories based on NOTCH2-Va expression (divided by quartile) the resulting classification was borderline significant (P = 5.9 × 10−2) as expected due to the small number of patients in each group. However, separation trend remained the same.